Skip to main content Skip to main navigation menu Skip to site footer

Five years survival and quality of life after radical nephrectomy: a descriptive single-center study

  • Adryansyah Can ,
  • Ginanda Putra Siregar ,
  • Bungaran Sihombing ,
  • Fauriski Febrian Papriska ,
  • Syah Mirsa Warli ,

Abstract

Introduction: Health-related quality of life (QoL) is an increasingly important factor in examining the benefits of different cancer treatments, such as radical nephrectomy for those with a renal mass presumed to be renal cell carcinoma (RCC). This study evaluates five years of survival rate, and quality of life of the patient after radical nephrectomy in our center.

Methods: This descriptive longitudinal study included thirty patients who were diagnosed as having renal mass in Urology division of H. Adam Malik General Hospital between January 2014 and December 2015. All patients were completely followed up for 5 years or until the patient died. We used a translated and validated Indonesian written European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ-C30) to assess the patient’s quality of life.

Results: Overall, 5-years survival of kidney tumor patients was 100%, 66.67%, 50%, 8.33%, respectively for stages 1 to 4. We found a sharp decrease in the cumulative survival rate of stage IV group in the first 24 months compared to the first 12 months, from 66.67% to 25%. This pattern of decrease was not found in the other group of stages. Overall, patients' quality of life had increased in the first three years postoperatively and decreased in the two years afterward. These fluctuations consistently occur in all groups. All of the groups had reached the maximum quality of life at the third year postoperatively.

Conclusion: Stage I renal cell carcinoma patients showed the best five-year survival rate and quality of life. The quality of life for all groups inclined for the first three years after surgery and decline consistently afterward.

Section

References

  1. van Oostenbrugge TJ, Fütterer JJ, Mulders PFA. Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review. Kidney cancer (Clifton, Va). 2018;2(2):79–93. Available from: https://pubmed.ncbi.nlm.nih.gov/30740580
  2. Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR, et al. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI cancer Spectr. 2019;3(1):pkz003–pkz003. Available from: https://pubmed.ncbi.nlm.nih.gov/31360891
  3. Kunath F, Schmidt S, Krabbe L-M, Miernik A, Dahm P, Cleves A, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane database Syst Rev. 2017;5(5):CD012045–CD012045. Available from: https://pubmed.ncbi.nlm.nih.gov/28485814
  4. Cairns P. Renal cell carcinoma. Cancer Biomark. 2010;9(1–6):461–73. Available from: https://pubmed.ncbi.nlm.nih.gov/22112490
  5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. Available from: http://dx.doi.org/10.3322/caac.20138
  6. Yang C, Liao Z. Comparison of Radical Nephrectomy and Partial Nephrectomy for T1 Renal Cell Carcinoma: A Meta-Analysis. Urol Int. 2018;101(2):175–83. Available from: http://dx.doi.org/10.1159/000490576
  7. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical Nephrectomy for Renal Cell Carcinoma: Long-Term Results and Prognostic Factors on a Series of 328 Cases. Eur Urol. 1997;31(1):40–8. Available from: http://dx.doi.org/10.1159/000474416
  8. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol. 2008/11/13. 2009;181(1):55–62. Available from: https://pubmed.ncbi.nlm.nih.gov/19012918
  9. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–52. Available from: http://dx.doi.org/10.1016/s0094-0143(03)00056-9
  10. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep. 2005;6(1):7–18. Available from: http://dx.doi.org/10.1007/s11934-005-0062-x
  11. Reese AC, Whitson JM, Meng M V. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol Semin Orig Investig. 2013;31(7):1305–9. Available from: http://dx.doi.org/10.1016/j.urolonc.2011.12.006
  12. Gangadaran SGD. Current Management Options in Metastatic Renal Cell Cancer. Oncol Rev. 2017;11(2):339. Available from: https://pubmed.ncbi.nlm.nih.gov/28680539
  13. Ljungberg B. The Role of Metastasectomy in Renal Cell Carcinoma in the Era of Targeted Therapy. Curr Urol Rep. 2012;14(1):19–25. Available from: http://dx.doi.org/10.1007/s11934-012-0293-6
  14. Eggener SE, Yossepowitch O, Kundu S, Motzer RJ, Russo P. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008/07/17. 2008;180(3):873–8. Available from: https://pubmed.ncbi.nlm.nih.gov/18635225
  15. Yücel ÖB, Tunç HM, Başaran M, Aras N. 22-year survival following radical nephrectomy and several metastasectomies in a case of renal cell carcinoma. Turkish J Urol. 2017/04/18. 2017;43(2):216–9. Available from: https://pubmed.ncbi.nlm.nih.gov/28717549
  16. Permpongkosol S, Bagga HS, Romero FR, Sroka M, Jarrett TW, Kavoussi LR. Laparoscopic Versus Open Partial Nephrectomy for the Treatment of Pathological T 1 N 0 M 0 Renal Cell Carcinoma: A 5-Year Survival Rate. J Urol. 2006;176(5):1984–9. Available from: http://dx.doi.org/10.1016/j.juro.2006.07.033
  17. Rampersaud EN, Klatte T, Bass G, Patard J-J, Bensaleh K, Böhm M, et al. The effect of gender and age on kidney cancer survival: Younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol Semin Orig Investig. 2014;32(1):30.e9-30.e13. Available from: http://dx.doi.org/10.1016/j.urolonc.2012.10.012
  18. Thiel DD, Davidiuk AJ, Broderick GA, Arnold M, Diehl N, Tavlarides A, et al. Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma. BMC Urol. 2015;15:58. Available from: https://pubmed.ncbi.nlm.nih.gov/26126615
  19. Bergman J, Gore JL, Singer JS, Anger JT, Litwin MS. Readability of Health Related Quality of Life Instruments in Urology. J Urol. 2010;183(5):1977–81. Available from: http://dx.doi.org/10.1016/j.juro.2009.12.107
  20. Gazmararian JA. Health Literacy Among Medicare Enrollees in a Managed Care Organization. JAMA. 1999;281(6):545. Available from: http://dx.doi.org/10.1001/jama.281.6.545
  21. Sitlinger A, Zafar SY. Health-Related Quality of Life: The Impact on Morbidity and Mortality. Surg Oncol Clin N Am. 2018/07/21. 2018;27(4):675–84. Available from: https://pubmed.ncbi.nlm.nih.gov/30213412
  22. Reviewer Guidance: Review of Human Pregnancy Outcome Data [Internet]. PsycEXTRA Dataset. Test accounts; 1999. Available from: http://dx.doi.org/10.1037/e330092004-001
  23. Parker PA, Swartz R, Fellman B, Urbauer D, Li Y, Pisters LL, et al. Comprehensive assessment of quality of life and psychosocial adjustment in patients with renal tumors undergoing open, laparoscopic and nephron sparing surgery. J Urol. 2012/01/15. 2012;187(3):822–6. Available from: https://pubmed.ncbi.nlm.nih.gov/22245327
  24. Quinten C, Coens C, Ghislain I, Zikos E, Sprangers MAG, Ringash J, et al. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer. 2015;51(18):2808–19. Available from: http://dx.doi.org/10.1016/j.ejca.2015.08.027
  25. Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10(9):865–71. Available from: http://dx.doi.org/10.1016/s1470-2045(09)70200-1
  26. Perwitasari DA, Atthobari J, Dwiprahasto I, Hakimi M, Gelderblom H, Putter H, et al. Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. Jpn J Clin Oncol. 2011;41(4):519–29. Available from: http://dx.doi.org/10.1093/jjco/hyq243
  27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. Available from: http://dx.doi.org/10.3322/caac.21166
  28. Krabbe L-M, Bagrodia A, Margulis V, Wood CG. Surgical management of renal cell carcinoma. Semin Intervent Radiol. 2014;31(1):27–32. Available from: https://pubmed.ncbi.nlm.nih.gov/24596437
  29. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75(5):799–810. Available from: http://dx.doi.org/10.1016/j.eururo.2019.02.011
  30. Tsui K-H, Shvarts O, Smith Rb, Figlin Ra, Dekernion Jb, Belldegrun A. Prognostic Indicators For Renal Cell Carcinoma: A Multivariate Analysis Of 643 Patients Using The Revised 1997 Tnm Staging Criteria. J Urol. 2000;163(4):1090–5. Available from: http://dx.doi.org/10.1016/s0022-5347(05)67699-9

How to Cite

Can, A., Siregar, G. P., Sihombing, B., Papriska, F. F., & Warli, S. M. (2021). Five years survival and quality of life after radical nephrectomy: a descriptive single-center study. Indonesia Journal of Biomedical Science, 15(1), 75–79. https://doi.org/10.15562/ijbs.v15i1.306

HTML
36

Total
15

Share

Search Panel

Adryansyah Can
Google Scholar
Pubmed
IJBS Journal


Ginanda Putra Siregar
Google Scholar
Pubmed
IJBS Journal


Bungaran Sihombing
Google Scholar
Pubmed
IJBS Journal


Fauriski Febrian Papriska
Google Scholar
Pubmed
IJBS Journal


Syah Mirsa Warli
Google Scholar
Pubmed
IJBS Journal